Continuous Renal Replacement Therapy
Role of Matrix Metalloproteases in Degradation of ECM
Factors Affecting Renal Clearance: Renal Impairment
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Serum Studies: Renal Function Tests
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Elena Rodríguez-Sánchez1, José Alberto Navarro-García1, Jennifer Aceves-Ripoll1
1Cardiorenal Translational Laboratory, Institute of Research i+12 (imas12), Hospital Universitario 12 de Octubre, 28041, Madrid, Spain.
Active matrix metalloproteinase-9 (MMP-9) levels differ across renal replacement therapies. On-line hemodiafiltration better controls MMP-9 than high-flux dialysis, and levels normalize after kidney transplantation.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: